Diasorin SpAWBO:DIAS +0.09%74 5-Year Yield-on-Cost % is 2.35 as of Jul. 06, 2026, which is 82% above its 10-year median of 1.29. GuruFocus rates WBO:DIAS with a GF Score™ of 74/100 and a GF Value™ of €89.88 (Modestly Undervalued). The stock has 6 warning signs investors should review. Among 64 Medical Diagnostics & Research companies, Diasorin SpA ranks worse than 53.13% on this metric.
Diasorin SpA's yield on cost for the quarter that ended in Dec. 2025 was 2.35.
The historical rank and industry rank for Diasorin SpA's 5-Year Yield-on-Cost % or its related term are showing as below:
WBO:DIAS'
s 5-Year Yield-on-Cost % Range Over the Past 10 Years
Min: 0.56 Med: 1.29 Max: 2.62
Current: 2.35
During the past 13 years, Diasorin SpA's highest Yield on Cost was 2.62. The lowest was 0.56. And the median was 1.29.
WBO:DIAS's 5-Year Yield-on-Cost % is ranked worse than 53.13% of 64
companies
in the Medical Diagnostics & Research industry
Industry Median: 2.395
vs WBO:DIAS: 2.35
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Diasorin SpA 5-Year Yield-on-Cost % Related Terms
WBO:DIAS vs TMO, DHR, IDXX: 5-Year Yield-on-Cost % Comparison
For the Diagnostics & Research subindustry, Diasorin SpA's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diasorin SpA 5-Year Yield-on-Cost % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diasorin SpA's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Diasorin SpA's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Therefore, Yield-on-Cost of Diasorin SpA is calculated as
Diasorin SpA (WBO:DIAS) has a 5-Year Yield-on-Cost % of 2.35 as of Jul. 06, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Diasorin SpA and its competitors. This is 82% above median its historical median of 1.29. Over the past decade, Diasorin SpA's 5-Year Yield-on-Cost % has ranged from 0.56 to 2.62. According to the industry distribution chart, Diasorin SpA ranks #34 out of 64 companies in the Medical Diagnostics & Research industry, placing it in the top 53.1%.
Is Diasorin SpA's 5-Year Yield-on-Cost % too high?
Diasorin SpA's current 5-Year Yield-on-Cost % of 2.35 is 82% above median its 10-year median of 1.29. Over the past 10 years, this metric has ranged from a low of 0.56 to a high of 2.62. The Medical Diagnostics & Research industry median 5-Year Yield-on-Cost % is 2.40. Diasorin SpA's value of 2.35 is 1.9% below this industry median. Based on the distribution chart, Diasorin SpA ranks #34 out of 64 companies in the Medical Diagnostics & Research industry, which is below the industry midpoint. Overall, Diasorin SpA has a GF Score™ of 74/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Diasorin SpA's 5-Year Yield-on-Cost % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diasorin SpA ranks #34 out of 64 companies for 5-Year Yield-on-Cost %. This places Diasorin SpA in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 2.40. Diasorin SpA's value of 2.35 is 1.9% below this benchmark. Historically, Diasorin SpA's own 5-Year Yield-on-Cost % has ranged from 0.56 to 2.62 over the past decade. While the company's 10-year median is 1.29 vs. the industry median of 2.40, Diasorin SpA has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Diagnostics & Research company?
The median 5-Year Yield-on-Cost % among Medical Diagnostics & Research companies is 2.40, based on 64 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diasorin SpA's current 5-Year Yield-on-Cost % of 2.35 is 1.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Diasorin SpA and its competitors. For the Medical Diagnostics & Research industry, the median 5-Year Yield-on-Cost % is 2.40 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diasorin SpA's current 5-Year Yield-on-Cost % is 2.35, which is 82% above median its own 10-year median of 1.29. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diasorin SpA stock overvalued right now?
Based on GuruFocus' analysis, Diasorin SpA (WBO:DIAS) is currently considered Modestly Undervalued. The stock's GF Value™ is €89.88, compared to a current price of €69.78 — trading 22.4% below its estimated fair value. The current 5-Year Yield-on-Cost % is 2.35, which is 82% above median its 10-year median of 1.29 and 1.9% below the Medical Diagnostics & Research industry median of 2.40. Diasorin SpA's overall GF Score™ is 74/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Diasorin SpA (WBO:DIAS), the current 5-Year Yield-on-Cost % is 2.35 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diasorin SpA (WBO:DIAS) Overvalued in 2026?
Based on GuruFocus' analysis, Diasorin SpA stock appears to be undervalued.
The current stock price of €69.78 is trading 22.4% below its estimated GF Value™ of €89.88.
GuruFocus considers Diasorin SpA to be Modestly Undervalued.
Key valuation signals for WBO:DIAS:
5-Year Yield-on-Cost %: 2.35 (82% above median its 10-year median of 1.29)
GF Value™: €89.88 vs. price of €69.78 (22.4% below fair value)
Industry Position: 1.9% below the Medical Diagnostics & Research median (#34 of 64)
No single metric tells the full story. See the WBO:DIAS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diasorin develops and manufactures a broad portfolio of in vitro diagnostics for detecting pathogens and sample contamination from the human body, as well as for use in industrial settings, such as food and water contamination testing. The company operates three segments: immunodiagnostics (69% of sales), molecular diagnostics (16%), and licensed technologies (14%). Diasorin was an important manufacturer of covid tests, which boosted its profits during the pandemic, but this segment's importance has decreased over the years, and in 2025, it accounted for only 1% of total sales.
74GF Score
Get the complete analysis for WBO:DIAS
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WBO:DIAS has been successfully added to your 